hotspot -WSS

hotspot

author：Wikipedia 2025-09-28 01:36:51 - browse：8

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Making the case for fair compensation in clinical trials

hotspot

WSS

Empower primary care with adequate payments and technology

The effects of a landmark ruling on DNA ownership are becoming clearer

How a small hospital in rural Puerto Rico survived Hurricane Maria

Primary care doctor shortage won't be solved by free med school tuition

Brain technologies pose threats that are all too real, experts warn

Eyeing GLP

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

United colonoscopy coverage change 'may cost lives,' doctors say

BIO to announce reorganization, senior leaders expected to depart

Alkermes shareholders re

Deliver public health messages at the right time

What does generative AI mean for health care? We asked experts

Study finds gene variants tied to breast cancer risk in Black women

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Moonlake's readout produced a cash windfall. Risks remain

Sepsis can kill a child within hours. Here's how hospitals are fighting back

focus

As billionaires fund anti

AltruBio raises $225 million to develop ulcerative colitis drug

Brain MRIs reveal impact of 'toxic stress' on Black children

Deliver public health messages at the right time

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Brain MRIs reveal impact of 'toxic stress' on Black children

focus

hotspot

Wikipedia

hotspot